Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
March 10, 2022 7:00 AM ESTAcquisition and integration of Strongbridge Biopharma completed; $50M in synergies to be realized by year-end 2022
Recorlev® approved by FDA
FY 21 pro forma net product revenues of $79M a 56% increase from prior year
Well-capitalized with cash, cash equivalents, and short-term investments of $102.4M at YE 2021
Double-digit net product revenues growth expected in 2022 to be $105M - $120M
Cash position further strengthened with a recent PIPE and the restructuring of debt with Hayfin Capital; 2022 year-end cash, cash equivalents,... More
